Anidulafungin versus Fluconazole for Invasive Candidiasis
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Anidulafungin, a new echinocandin, has potent activity against candida species. We compared anidulafungin with fluconazole in a randomized, double-blind, noninferiority trial of treatment for invasive candidiasis. METHODS: Adults with invasive candidiasis were randomly assigned to receive either intravenous anidulafungin or intravenous fluconazole. All patients could receive oral fluconazole after 10 days of intravenous therapy. The primary efficacy analysis assessed the global response (clinical and microbiologic) at the end of intravenous therapy in patients who had a positive baseline culture. Efficacy was also assessed at other time points. RESULTS: Eighty-nine percent of the 245 patients in the primary analysis had candidemia only. Candida albicans was isolated in 62% of the 245 patients. In vitro fluconazole resistance was infrequent. Most of the patients (97%) did not have neutropenia. At the end of intravenous therapy, treatment was successful in 75.6% of patients treated with anidulafungin, as compared with 60.2% of those treated with fluconazole (difference, 15.4 percentage points; 95% confidence interval [CI], 3.9 to 27.0). The results were similar for other efficacy end points. The statistical analyses failed to show a "center effect"; when data from the site enrolling the largest number of patients were removed, success rates at the end of intravenous therapy were 73.2% in the anidulafungin group and 61.1% in the fluconazole group (difference, 12.1 percentage points; 95% CI, -1.1 to 25.3). The frequency and types of adverse events were similar in the two groups. The rate of death from all causes was 31% in the fluconazole group and 23% in the anidulafungin group (P=0.13). CONCLUSIONS: Anidulafungin was shown to be noninferior to fluconazole in the treatment of invasive candidiasis. (ClinicalTrials.gov number, NCT00056368 [ClinicalTrials.gov]).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The echinocandins, as first-line therapy for most Candida infections, have an overall failure rate of 25–30% in invasive candidiasis in clinical trials, and notably have little activity within the urinary tract.18,133,140–144”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [141]
In the citing paper
“Although morbidity and mortality associated with invasive Candida infections remains high, only four major classes of antifungal agents are currently approved for systemic therapy.”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [141]
In the citing paper
“The echinocandins, as first-line therapy for most Candida infections, have an overall failure rate of 25–30% in invasive candidiasis in clinical trials, and notably have little activity within the urinary tract.18,133,140–144”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [141]
In the citing paper
“Safety and tolerability were similar between the two groups and were consistent with the reported safety profile of echinocandin class drugs. 22-26”
In the citing paper
“A randomized controlled trial, more robust for examining effects of treatment, found superior outcomes for patients who received an echinocandin as primary treatment for invasive candidiasis [12].”
From Treatment practices for adults with candidemia at 9 active surveillance sites—United States, 2017–2018. (2021) · cites this paper as [12]
6 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Wisplinghoff, H., Bischoff, T., Tallent, S. M., Seifert, H., Wenzel, R. P., & Edmond, M. B. (2004) · Clinical Infectious Diseases · doi:10.1086/421946 · Cited by 4,496
Guidelines for Treatment of Candidiasis
Pappas, P. G., Rex, J. H., Sobel, J. D., Filler, S. G., Dismukes, W. E., Walsh, T. J., & Edwards, J. E. (2004) · Clinical Infectious Diseases · doi:10.1086/380796 · Cited by 1,440
Self-citationComparison of Caspofungin and Amphotericin B for Invasive Candidiasis
Mora-Duarte, J., Betts, R., Rotstein, C., Colombo, A. L., Thompson-Moya, L., Smietana, J., Lupinacci, R., Sable, C., Kartsonis, N., & Perfect, J. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021585 · Cited by 1,380
Self-citationSecular Trends in the Epidemiology of Nosocomial Fungal Infections in the United States, 1980-1990
Sague, C. M. B., Jarvis, W. R., & System, N. N. I. S. (1993) · Journal of Infectious Diseases · doi:10.1093/infdis/167.5.1247 · Cited by 1,140
Denning, D. W. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14472-8 · Cited by 1,131
Rex, J. H., Bennett, J. E., Sugar, A. M., Pappas, P. G., van der Horst, C. M., Edwards, J. E., Washburn, R. G., Scheld, W. M., Karchmer, A. W., Dine, A. P., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199411173312001 · Cited by 1,039
Self-citationTrick, W. E., Fridkin, S. K., Edwards, J. R., Hajjeh, R. A., Gaynes, R. P., & Hospitals, T. N. N. I. S. S. (2002) · Clinical Infectious Diseases · doi:10.1086/342300 · Cited by 660
Kullberg, B., Sobel, J., Ruhnke, M., Pappas, P., Viscoli, C., Rex, J., Cleary, J., Rubinstein, E., Church, L., Brown, J., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67490-9 · Cited by 521
Self-citationRex, J. H., Pappas, P. G., Karchmer, A. W., Sobel, J., Edwards, J. E., Hadley, S., Brass, C., Vazquez, J. A., Chapman, S. W., Horowitz, H. W., et al. (2003) · Clinical Infectious Diseases · doi:10.1086/374850 · Cited by 495
Self-citationPark, S., Kelly, R., Kahn, J. N., Robles, J., Hsu, M.-J., Register, E., Li, W., Vyas, V., Fan, H., Abruzzo, G., et al. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.8.3264-3273.2005 · Cited by 434
Research works printed but not linked: 4
- Graybill JR, 2001, Curr Opin Investig Drugs, 2, 468
- Espinel-Ingroff A, 2003, Rev Iberoam Micol, 20, 121
- Park S, Paderu P, Perlin DS. Amino acid polymorphisms in Fks1 from C. parapsilosis, C. metapsilosis and C. orthopsilosis strains account for intrinsic reduced susceptibility to echinocandin drugs. In: Program and Abstracts of the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 27-30, 2006.
- 10.1002/(SICI)1097-0258(19960830)15:16<1729::AID-SIM334>3.0.CO;2-M · doi:10.1002/(sici)1097-0258(19960830)15:16<1729::aid-sim334>3.0.co;2-m
Cited by
Items 801–892 of 892
Micafungin and caspofungin pharmacodynamics in patients with candidemia
Kassar, R., Chang, J., Jerome, S., & Coleman, R. (2018) · Journal of Infectious Diseases and Immunity · doi:10.5897/jidi2018.0180
Espinel‐Ingroff, A., Sanguinetti, M., & Posteraro, B. (2019) · Current Fungal Infection Reports · doi:10.1007/s12281-019-0336-2
Antifungal Consideration for Transplant Recipients
Dubrovskaya, Y., Merl, M. Y., Perlin, D. S., & Safdar, A. (2019) · Springer eBooks · doi:10.1007/978-1-4939-9034-4_52
Cotner, S. E., & Dawson, K. L. (2019) · Current treatment options in infectious diseases/Current treatment options in infectious disease · doi:10.1007/s40506-019-00208-2
Candida Infections in Intensive Care Unit: How to Treat?
Kazak, E. (2020) · Klimik Dergisi/Klimik Journal · doi:10.5152/kd.2019.60 · Cited by 1
“Başka bir çalışmada anidulafunginin fungemideki eradikasyon oranının flukonazolden daha düşük olduğu saptanmıştır (52).”
Widayana, K. A., Aryabiantara, I. W., Senapathi, T. G. A., Suranadi, I. W., & Aribawa, I. G. N. M. (2019) · Neurologico Spinale Medico Chirurgico · doi:10.36444/nsmc.v2i3.83
Issues and Concerns in the Management of Systemic Candidiasis
Fong, I. W. (2020) · Springer eBooks · doi:10.1007/978-3-030-36966-8_11
New Immunological Technique for Diagnosis of Candida albicans Infection
Hassan, R. (2020) · Aalborg Academy Journal of Medical Sciences · doi:10.32441/aajms.3.2.10
Clancy, C. J. (2014) · AAPS advances in the pharmaceutical sciences series · doi:10.1007/978-1-4939-1304-6_10
“Fluconazole demonstrated efficacy similar to echinocandins and amphotericin B deoxycholate in randomized clinical trials for the treatment of candidemia (Rex et al. 1994, 2003; Mora-Duarte et al. 2002; Reboli et al. 2007).”
BackgroundPilzinfektionen in der Intensivmedizin
Richter, D., Lichtenstern, C., Brinkmann, A., & Weigand, M. A. (2020) · Intensivmedizin up2date · doi:10.1055/a-1067-2797
“Zum Beispiel zeigte sich Anidulafungin gegenüber Fluconazol in der Behandlung einer Candidämie in einer sekundären Auswertung überlegen (Ansprechrate für Fluconazol: 60,2%, für Anidulafungin: 75,6%, Differenz: 15,4% [3,9; 27,0]) [32].”
BackgroundInfluentialMcCullough, B. (2017) · The American Pharmacists Association eBooks · doi:10.21019/pharmacotherapyfirst.fungal_overview
Pilzinfektionen in der Intensivmedizin
Richter, D., Lichtenstern, C., Brinkmann, A., & Weigand, M. A. (2021) · Krankenhaushygiene up2date · doi:10.1055/a-1338-9359
“Zum Beispiel zeigte sich Anidulafungin gegenüber Fluconazol in der Behandlung einer Candidämie in einer sekundären Auswertung überlegen (Ansprechrate für Fluconazol: 60,2%, für Anidulafungin: 75,6%, Differenz: 15,4% [3,9; 27,0] [32]).”
BackgroundInfluentialUtzolino, S. (2021) · Springer eBooks · doi:10.1007/978-3-662-62508-8_11
Salim, S., Afzal, R. K., Hassan, S., Ikram, A., Hussain, A., & Khan, M. (2021) · Pakistan Armed Forces Medical Journal · doi:10.51253/pafmj.v71i3.5190
Sachdeva, M. M., & Durand, M. L. (2014) · Current Fungal Infection Reports · doi:10.1007/s12281-014-0206-x
“Echinocandins are also effective in treating candidemia, including that due to fluconazole-resistant strains [48,49,39].”
BackgroundGebretekle, G. B., Fentie, A. M., Gebremariam, G. T., Ali, E. E., Erku, D., Alemayehu, T., Abebe, W., & Sander, B. (2022) · Research Square · doi:10.21203/rs.3.rs-1214746/v1
(2021) · Elsevier eBooks · doi:10.1016/b978-3-437-23841-3.00041-2
Pagano, L., & Caira, M. (2011) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.8247956.8674054
Fungal Infections in Cancer Patients
Granwehr, B. P., Sipsas, N. V., & Kontoyiannis, D. P. (2019) · Springer eBooks · doi:10.1007/978-3-319-74698-2_121-1
(2008) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0b013e3282ff8c19
Lepak, A. J., & Andes, D. R. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-819990-9.00018-4
Knapp, K. M., & Flynn, P. M. (2009) · Elsevier eBooks · doi:10.1016/b978-1-4160-4044-6.50217-x
New Drugs: Influenza H5N1 vaccines
(2009) · Australian Prescriber · doi:10.18773/austprescr.2009.083
Fungal cardiovascular infections
Drake, S., & Sandoe, J. A. T. (2017) · Oxford University Press eBooks · doi:10.1093/med/9780198755388.003.0021
Anidulafungina en niños: experiencia de un hospital pediátrico de tercer nivel en Argentina
(2017) · Archivos Argentinos de Pediatria · doi:10.5546/aap.2017.374
Zheng, Y., Xie, T., Wu, L., Liu, X., Zhu, L., Chen, Y., Mao, E., Li-Zhong, H. A. N., Er-Zhen, C. H. E. N., & Yang, Z. (2020) · Research Square · doi:10.21203/rs.2.24729/v1
Fresenius, M., & Heck, M. C. (2011) · Springer eBooks · doi:10.1007/978-3-642-16879-6_15
Kauffman, C. A. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-1604-7.00346-8
(2009) · Australian Prescriber · doi:10.18773/austprescr.2009.081
&NA; (2010) · Drugs & Therapy Perspectives · doi:10.2165/11206200-000000000-00000
(2013) · Elsevier eBooks · doi:10.1016/b978-3-437-22073-9.00003-6
Antibiotika, Prophylaxe und Antimykotika
Lemmen, S. (2011) · Springer eBooks · doi:10.1007/978-3-642-16929-8_62
Freissmuth, M. (2012) · Springer-Lehrbuch · doi:10.1007/978-3-642-12354-2_59
Collins, C., & Rogers, T. R. (2011) · Springer eBooks · doi:10.1007/978-88-470-1601-9_7
New Drugs: Vaccinia smallpox vaccine
(2009) · Australian Prescriber · doi:10.18773/austprescr.2009.086
Fungal infections in haemato-oncology
Koehler, P. A., & Cornely, O. A. (2017) · Oxford University Press eBooks · doi:10.1093/med/9780198755388.003.0032
Smith, P. B., & Benjamin, D. K. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4377-0755-7.00226-8
Recent Publications on Medications and Pharmacy
Sterling, J. A. (2007) · Hospital Pharmacy · doi:10.1310/hpj4208-768
Schrey, D., Walsh, T. J., & Groll, A. H. (2010) · Side effects of drugs annual · doi:10.1016/s0378-6080(10)32027-7 · Cited by 1
Self-citationThompson, G. R., & Patterson, T. F. (2014) · Springer eBooks · doi:10.1007/978-3-662-44000-1_15
Fungal infections in solid organ transplantation
James, D. A., Shah, A., & Reed, A. K. (2017) · Oxford University Press eBooks · doi:10.1093/med/9780198755388.003.0034
Freissmuth, M. (2016) · Springer-Lehrbuch · doi:10.1007/978-3-662-46689-6_59
Fresenius, M. (2014) · Springer eBooks · doi:10.1007/978-3-642-44933-8_15
Echinocandins for Prevention and Treatment of Invasive Fungal Infections
Johnson, M. D., & Mohr, J. (2009) · CRC Press eBooks · doi:10.3109/9780849387869-14 · Cited by 2
New Drugs: Influenza H1N1 vaccine
(2009) · Australian Prescriber · doi:10.18773/austprescr.2009.082
(2015) · Elsevier eBooks · doi:10.1016/b978-0-444-53717-1.00672-7
(2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw454
New Drugs: Methoxy polyethylene glycol-epoetin beta
(2009) · Australian Prescriber · doi:10.18773/austprescr.2009.085
(2015) · Elsevier eBooks · doi:10.1016/b978-0-444-53717-1.00017-2
(2015) · Elsevier eBooks · doi:10.1016/b978-0-444-53717-1.00752-6
C. parapsilosis: The importance of an emerging pathogen
Martín-Gómez, M. T., & Puig‐Asensio, M. (2022) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1016/j.eimc.2022.09.005
Therapie von Infektionen bei Tumorpatienten
Schmidt‐Hieber, M., Teschner, D., Desole, M., Link, H., Maschmeyer, G., & Schalk, E. (2022) · Springer Reference Medizin · doi:10.1007/978-3-662-46764-0_155-1
Caspofungina no tratamento de infecção mista por Candida albicans e Staphylococcus aureus.
Scheunemann, G. S. (2020) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.42.2020.tde-13012022-173246
Profilaxia de Infecções Fúngicas em Pacientes Transplantados: O que Mudou nos Últimos Anos?
Silva, M. A. M., Callera, F., & Leão, M. V. P. (2023) · Brazilian Journal of Transplantation · doi:10.53855/bjt.v26i1.475_port
Prophylaxis of Fungal Infections in Transplant Patients:What has Changed in Recent Years?
Silva, M. A. M., Callera, F., & Leão, M. V. P. (2023) · Brazilian Journal of Transplantation · doi:10.53855/bjt.v26i1.475_eng
C. parapsilosis: The importance of an emerging pathogen
Martín-Gómez, M. T., & Puig‐Asensio, M. (2023) · Enfermedades infecciosas y microbiologia clinica (English ed ) · doi:10.1016/j.eimce.2022.09.010
Araujo, J. M. (2023) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.5.2023.tde-05022024-163245
Incidence and Challenges in Management of Blood Stream Infections in Hemodialysis
Khatun, N., Khan, A., Arfat, M., Siddiqui, S., & Khan, S. A. (2023) · International Journal of Membrane Science and Technology · doi:10.15379/ijmst.v10i5.3570
Murguía-Pérez, J. G., & Arce‐Cabrera, D. (2023) · Alergia, Asma e Inmunología Pediátricas · doi:10.35366/115244
Sahithi, B., & Reddy, M. S. (2023) · International Journal of Science and Research (IJSR) · doi:10.21275/mr231121114209
Gaifer, Z., Alahmadi, B. A. R., Demyati, M. W., & Mohammed, M. (2024) · Saudi Journal of Medical and Pharmaceutical Sciences · doi:10.36348/sjmps.2024.v10i07.001
Santos, C. A. Q., Won, S. Y., Dwyer, R., Perez, C., & Trick, W. E. (2025) · Infection Control and Hospital Epidemiology · doi:10.1017/ice.2024.210
Catheter-Associated Bloodstream Infections in the Intensive Care Units
Chakraverty, R., & Kundu, A. K. (2024) · Springer eBooks · doi:10.1007/978-981-96-0018-2_4
Groll, A. H., & Walsh, T. J. (2025) · Elsevier eBooks · doi:10.1016/b978-0-323-82763-8.00256-9
Self-citationOpportunistic Infections in Hematopoietic Stem Cell Transplantation
Dara, J. S., & Dvorak, C. C. (2025) · Elsevier eBooks · doi:10.1016/b978-0-323-82763-8.00071-6
Cornely, O. A. (2025) · Elsevier eBooks · doi:10.1016/b978-3-437-21194-2.00014-x
Treatment of Invasive Fungal Disease During Therapy for Acute Lymphoblastic Leukemia
Alharbi, I., Nassif, A., & Hennawi, Y. B. (2025) · Journal of Medical Cases · doi:10.14740/jmc5066
“IA patients are reported to have a death rate of 28-42% three months following diagnosis [15].”
Bubna, A. K. (2025) · Springer eBooks · doi:10.1007/978-981-95-3791-4_20
Fatal Complications in Candida parapsilosis Endocarditis—A Case Report
Smâdu, S., Tetradov, S. C., Ene, L., Florescu, S. A., & Lazăr, D. Ș. (2025) · Journal of Fungi · doi:10.3390/jof11110817
“[18].”
Recent Publications on Medications and Pharmacy
Sterling, J. A. (2008) · Hospital Pharmacy · doi:10.1310/hpj4312-1024
The diagnosis and management of systemic candidiasis in the Intensive Care Unit
Big, C., & Vazquez, J. A. (2015)
Fricke, U., & Schwabe, U. (2008) · Springer eBooks · doi:10.1007/978-3-540-69219-5_2 · Cited by 1
Schroeder, M. L., Weber, T., Denker, T., Winterland, S., Wichmann, D., Rohde, H., Ozga, A.-K., Fischer, M., & Kluge, S. (2020) · Figshare · doi:10.6084/m9.figshare.13106465
Schroeder, M. L., Weber, T., Denker, T., Winterland, S., Wichmann, D., Rohde, H., Ozga, A.-K., Fischer, M., & Kluge, S. (2020) · Figshare · doi:10.6084/m9.figshare.13106456
Schroeder, M. L., Weber, T., Denker, T., Winterland, S., Wichmann, D., Rohde, H., Ozga, A.-K., Fischer, M., & Kluge, S. (2020) · Figshare · doi:10.6084/m9.figshare.13106462
Schroeder, M. L., Weber, T., Denker, T., Winterland, S., Wichmann, D., Rohde, H., Ozga, A.-K., Fischer, M., & Kluge, S. (2020) · Figshare · doi:10.6084/m9.figshare.13106453
Schroeder, M. L., Weber, T., Denker, T., Winterland, S., Wichmann, D., Rohde, H., Ozga, A.-K., Fischer, M., & Kluge, S. (2020) · Figshare · doi:10.6084/m9.figshare.13106459
Additional file 1 of Accounting for center-level effects in multicenter randomized controlled trials
Islam, S., & Bangdiwala, S. I. (2024) · Figshare · doi:10.6084/m9.figshare.26735643
Fang, W., Hu, B., Liu, F., Liu, J., Shang, X., Wang, C., Yang, X., Zhang, S., Pan, A., Liu, J., et al. (2026) · Journal of Intensive Medicine · doi:10.1016/j.jointm.2025.10.009
Antifungal activity of rezafungin in invasive candidiasis: From bench to bed
Quindós, G., García‐Vidal, C., Martin-Martitegui, X., & Zaragoza, R. (2026) · Revista Iberoamericana de Micología · doi:10.1016/j.riam.2026.02.001 · Cited by 1
Allebone-Salt, P. E., Wake, R. M., White, P. L., Price, J. S., Harrison, T., & Bicanic, T. A. (2026) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2024.0341
Clinical controversies in the management of candidemia in adults and children
Cluck, D. B., White, B. P., Hilzendager, S. A., Ryder, J. H., Tu, P. J., McPherson, A. Z., Rogers, D. J., & Chastain, D. B. (2026) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxag212
Management of invasive fungal infections in the intensive care unit
Chean, D., Friol, A., Azoulay, É., & Maillard, A. (2026) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2026.2710718
“Another echinocandin, anidulafungin, was noninferior to fluconazole in terms of treatment success of IC (75% versus 60%, respectively) [122].”
Martín‐Loeches, I., & Yu, Y. (2026) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2026.2726965
Mendes, J. (2012) · Revista Portuguesa de Doenças Infecciosas (RPDI) · doi:10.65332/rpdi.v8.215 · Cited by 5
Lodise, T. P., & Patel, N. (2026) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofag563
Echinocandins: Advances in antifungal therapy
Vadlapatla, R., & Yotnotsian, Y. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-44037-3.00375-4
Structural basis of caspofungin inhibition of Nakaseomyces glabratus Fks1Preprint
Rasel, M. S. I., Raghav, D., Suchana, F. J., de Carvalho, R. S. A., & Tomasiak, T. M. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.10.21.760291
Invasive fungal infections in critically ill patients
Meersseman, W. (2008)
Antibiotika, Antibiotikaprophylaxe und Antimykotika in der Intensivmedizin
Lemmen, S. (2015) · Springer eBooks · doi:10.1007/978-3-642-54675-4_82-1
Metadata
- Authors
- Reboli, A. C., Rotstein, C., Pappas, P. G., Chapman, S. W., Kett, D. H., Kumar, D., Betts, R., Wible, M., Goldstein, B. P., Schranz, J., Krause, D. S., & Walsh, T. J.
- Affiliations
- Cooper University Hospital (US)
- Hamilton Health Sciences (CA)
- University of Alabama at Birmingham (US)
- University of Mississippi (US)
- University of Miami (US)
- University Health Network (CA)
- University of Rochester (US)
- Vifor Pharma (Germany) (DE)
- National Institutes of Health (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-06-14
- Volume
- 356
- Issue
- 24
- Pages
- 2472-2482
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2126319933
- Cited by
- 894
- References
- 27
- Citations by year
- 2026: 13 · 2025: 22 · 2024: 21 · 2023: 33 · 2022: 23 · 2021: 37 · 2020: 47 · 2019: 34 · 2018: 40 · 2017: 29 · 2016: 34 · 2015: 44 · 2014: 46 · 2013: 55 · 2012: 52
- FWCI
- 58.30
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Department of Veterans Affairs
- Eli Lilly and Company
- Pfizer
- Viropharma
- Astellas Pharma
- Basilea Pharmaceutica
- Duke Clinical Research Institute
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Life Sciences › Agricultural and Biological Sciences › Plant Science › Fungal Plant Pathogen Control
- Keywords
- anidulafungin, fluconazole, invasive candidiasis, echinocandins, candidemia, Candida albicans, non-inferiority, antifungal therapy, mortality, fluconazole resistance
- MeSH terms
- Anidulafungin, Adolescent, Adult, Aged, Aged, 80 and over, Antifungal Agents, Candida, Candidiasis, Double-Blind Method, Female, Humans, Infusions, Intravenous, Male, Middle Aged, Peptides, Cyclic, Fluconazole, Fungemia, Treatment Outcome, Kaplan-Meier Estimate, Echinocandins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.